Vanda Pharmaceuticals
VNDA
146 hedge funds and large institutions have $202M invested in Vanda Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 54 reducing their positions, and 18 closing their positions.
1.49% more ownership
Funds ownership: 74% → 75.49% (+1.5%)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
0% more funds holding
Funds holding: 146 → 146 (0)
2% less capital invested
Capital invested by funds: $207M → $202M (-$4.52M)
15% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 54
77% less call options, than puts
Call options by funds: $748K | Put options by funds: $3.23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.86M |
| 2 |
KAM
Krensavage Asset Management
New York
|
+$1.75M |
| 3 |
Citigroup
New York
|
+$1.58M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$1.33M |
| 5 |
Universal-Beteiligungs- und Servicegesellschaft
Frankfurt Am Main,
Germany
|
+$888K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.98M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$1.73M |
| 3 |
Renaissance Technologies
New York
|
-$1.34M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$916K |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
-$905K |
VNDA Hedge Fund Activity: Q1 2025 in Review
146 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2025, worth a combined $202M — down 2.2% from $207M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new VNDA positions and 18 closed out — a net gain of 1 holder — while 46 added to existing stakes and 54 trimmed.
The largest buyer was Millennium Management, adding an estimated $6.86M. The largest seller was Morgan Stanley, cutting an estimated $1.98M.
- 146 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $202M of Vanda Pharmaceuticals stock for Q1 2025, down 2.2% quarter-over-quarter.
- 19 funds opened new Vanda Pharmaceuticals positions in Q1 2025 and 18 closed out, a net change of +1 holder.
- The largest Vanda Pharmaceuticals buyer in Q1 2025 was Millennium Management, an estimated $6.86M added.
- The largest Vanda Pharmaceuticals seller in Q1 2025 was Morgan Stanley, an estimated $1.98M sold.
Based on aggregated 13F filings for Q1 2025.